• No image available for this medication
    • PROMACTA (Brand for ELTROMBOPAG OLAMINE)

ELTROMBOPAG (el TROM boe pag) helps your body make more platelets. It is used to treat low platelets caused by chronic immune (idiopathic) thrombocytopenic purpura (ITP) or chronic hepatitis C infection. It is also used in patients with severe aplastic anemia.


PROMACTA (Brand for ELTROMBOPAG OLAMINE) Lifestyle Interactions

  • Eltrombopag Olamine 75mg, Oral tablet

    Interaction: food high in calcium
    Severity: Major
    Notes for Consumers: Take Eltrombopag 1 hour before or 4 hours after you have food. Foods high in calcium may decrease the amount of Eltrombopag absorbed by the stomach, which can decrease the effects of Eltrombopag.
    Notes for Professionals: Eltrombopag chelates polyvalent cations (e.g., calcium, aluminum, and magnesium) in food. Systemic exposure to eltrombopag may be decreased when it is coadministered with a polyvalent cation-containing product. Eltrombopag should not be taken within 4 hours of any oral products containing polyvalent cations, such as calcium salts.
  • Eltrombopag Olamine 75mg, Oral tablet

    Interaction: Foods High in Iron
    Severity: Major
    Notes for Consumers: Take Eltrombopag 1 hour before or 4 hours after you have food. Foods high in iron may decrease the amount of Eltrombopag absorbed by the stomach, which can decrease the effects of Eltrombopag.
    Notes for Professionals: Eltrombopag chelates polyvalent cations (e.g., calcium, aluminum, and magnesium) in food. Systemic exposure to eltrombopag may be decreased when it is coadministered with a polyvalent cation-containing product. Eltrombopag should not be taken within 4 hours of any oral products containing polyvalent cations, such as aluminum salts, (like aluminum hydroxide), calcium salts, (including calcium carbonate), and magnesium salts.
  • Eltrombopag Olamine 75mg, Oral tablet

    Interaction: Tobacco
    Severity: Moderate
    Notes for Consumers: Tobacco may decrease the actions of Eltrombopag. Although an interaction is possible, these drugs may be used together. Your drug therapy will be closely monitored by your health care provider.
    Notes for Professionals: Eltrombopag is metabolized by CYP1A2. The significance of administering inducers of CYP1A2, such as tobacco, on the systemic exposure of eltrombopag has not been established. Monitor patients for a decrease in the efficacy of eltrombopag if these drugs are coadministered.

DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment. Drug information is sourced from GSDD (Gold Standard Drug Database ) provided by Elsevier.